The loss of Veracyte under GAAP for the 3 months of 2022 was $14.461 million, down 2.9 times from $41.868 million in the previous year. Revenue increased 84.7% to $67.783 million from $36.703 million a year earlier.
The loss of Veracyte under GAAP for the 3 months of 2022 was $14.461 million, down 2.9 times from $41.868 million in the previous year. Revenue increased 84.7% to $67.783 million from $36.703 million a year earlier. 
investor.veracyte.com
English (US) 